Cencora slides 17.6% after fiscal Q2 results miss revenue expectations and highlight near-term headwinds

Cencora, Inc. (COR) is down 17.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to Cencora’s fiscal Q2 results missing expectations, with investors focusing on the revenue shortfall and commentary pointing to pressure in its largest U.S. segment. Even though the company raised its full-year adjusted EPS outlook, the market reaction suggests concern about demand mix, customer-related headwinds, and pricing dynamics outweighing the profit-guide lift.

Details:

Cencora reported fiscal Q2 (ended March 31, 2026) revenue of $78.4 billion and adjusted diluted EPS of $4.75.

The company updated fiscal 2026 adjusted diluted EPS guidance to $17.65 to $17.90 (up from its prior range).

Cencora said its U.S. Healthcare Solutions segment revenue rose to $68.8 billion, but growth was affected by branded-drug price cuts, lower sales to a large mail-order client, and prior customer losses.

The company also said it expects to repurchase $1 billion in shares by the end of calendar 2026.

Sources:

Business Wire, SEC (Form 8-K), Reuters

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$COR Insider Trading Activity

$COR insiders have traded $COR stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $COR stock by insiders over the last 6 months:

ROBERT P. MAUCH (President & CEO) has made 0 purchases and 4 sales selling 19,050 shares for an estimated $6,776,655.
LAZARUS KRIKORIAN (SVP & Chief Accounting Officer) sold 4,031 shares for an estimated $1,383,580
ELIZABETH S CAMPBELL (Executive Vice President) sold 3,351 shares for an estimated $1,146,377
SILVANA BATTAGLIA (Executive Vice President) sold 1,677 shares for an estimated $578,565

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$COR Hedge Fund Activity

We have seen 648 institutional investors add shares of $COR stock to their portfolio, and 649 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,321,566 shares (-73.2%) from their portfolio in Q4 2025, for an estimated $1,459,608,916
FMR LLC added 2,148,227 shares (+64.9%) to their portfolio in Q4 2025, for an estimated $725,563,669
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,085,473 shares (+80.9%) to their portfolio in Q4 2025, for an estimated $704,368,505
MARSHALL WACE, LLP removed 1,839,818 shares (-92.2%) from their portfolio in Q4 2025, for an estimated $621,398,529
VIKING GLOBAL INVESTORS LP removed 1,778,135 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $600,565,096
CITADEL ADVISORS LLC removed 1,185,912 shares (-95.8%) from their portfolio in Q4 2025, for an estimated $400,541,778
PRICE T ROWE ASSOCIATES INC /MD/ removed 731,075 shares (-9.5%) from their portfolio in Q4 2025, for an estimated $246,920,581

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$COR Congressional Stock Trading

Members of Congress have traded $COR stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $COR stock by members of Congress over the last 6 months:

REPRESENTATIVE JARED MOSKOWITZ has traded it 3 times. They made 3 purchases worth up to $45,000 on 03/31, 03/23 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$COR Analyst Ratings

Wall Street analysts have issued reports on $COR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Morgan Stanley issued a "Overweight" rating on 01/29/2026
TD Cowen issued a "Buy" rating on 11/10/2025

To track analyst ratings and price targets for $COR, check out Quiver Quantitative's $COR forecast page.

$COR Price Targets

Multiple analysts have issued price targets for $COR recently. We have seen 8 analysts offer price targets for $COR in the last 6 months, with a median target of $409.5.

Here are some recent targets:

John Belton from Evercore ISI Group set a target price of $360.0 on 04/08/2026
Glen Santangelo from Barclays set a target price of $425.0 on 02/13/2026
Stephen Baxter from Wells Fargo set a target price of $429.0 on 02/10/2026
Lisa Gill from JP Morgan set a target price of $419.0 on 02/10/2026
Erin Wright from Morgan Stanley set a target price of $400.0 on 01/29/2026
Brian Tanquilut from Jefferies set a target price of $440.0 on 01/22/2026
Michael Funk from B of A Securities set a target price of $360.0 on 01/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.